Impact of Biosimilar Insulins on Clinical Practice: Meeting Report
about
Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus® Insulin Glargine.Biosimilar insulins: Informed choice for South Asia.The Future of Biosimilar Insulins.Biosimilar insulins: An unavoidable option in South-East Asia.
P2860
Impact of Biosimilar Insulins on Clinical Practice: Meeting Report
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Impact of Biosimilar Insulins on Clinical Practice: Meeting Report
@ast
Impact of Biosimilar Insulins on Clinical Practice: Meeting Report
@en
type
label
Impact of Biosimilar Insulins on Clinical Practice: Meeting Report
@ast
Impact of Biosimilar Insulins on Clinical Practice: Meeting Report
@en
prefLabel
Impact of Biosimilar Insulins on Clinical Practice: Meeting Report
@ast
Impact of Biosimilar Insulins on Clinical Practice: Meeting Report
@en
P2093
P356
P1476
Impact of Biosimilar Insulins on Clinical Practice: Meeting Report
@en
P2093
Huub Schellekens
Philip Home
Richard O Dolinar
Shefali Goyal
Steve Edelman
William H Polonsky
P304
P356
10.1177/1932296813518267
P577
2014-01-01T00:00:00Z